The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in…
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.
